ArticleThe oncologist2025
Pathomic immune biomarkers define recurrence risk in early-stage melanoma.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.Research square · 2026Article
- The gut-skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management.Frontiers in microbiology · 2026Review
- Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.Therapeutic advances in vaccines and immunotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundThere is an urgent need for biomarkers in early-stage melanoma because the benefit of adjuvant immunotherapy is marginal while the toxicity is considerable. Immune surveillance is a key mechanism limiting melanoma progression, but no immune biomarkers have yet been sufficiently validated for clinical use.
methodsWe validate 3 digital pathology biomarkers, all previously trained in published cohorts and testable in formalin fixed paraffin embedded specimens, for correlation with recurrence free survival and distant metastatic free survival: (1) tumor infiltrating lymphocytes identified using artificial intelligence in digital images (eTILs), (2) nanoString melanoma immune profile (MIP), and (3) quantitative immunofluorescence of CD8+ cells.
resultsThree immune biomarkers were validated and found to correlate with recurrence at 36 months by receiver operating curve analysis (eTILs area under the curve [AUC] = 0.706, P = .002; MIP AUC = 0.775, P < .001; and CD8% AUC = 0.682, P = .009) and define high and low risk groups using Kaplan Meier (KM) curves within the IIA-IIID population (P = .007 for eTILs and P < .001 for MIP and CD8%) and within the difficult to treat IIB-IIIA subset (P = .005, P < .001, P < .001, respectively). Immune biomarkers enhance clinical predictors (P = .012, P < .001, P = .004), and correlate with distant metastatic recurrence (P = .031, P = .047, P = .014, respectively). Network analysis shows that stage and depth combined with pathomic immune features yields the highest correlation with recurrence (AUC = 0.875, P < .001).
conclusionsImmune biomarkers should be prospectively validated in stage II-III melanoma for the purpose of avoiding overtreatment of low-risk patients and to stratify high-risk patients for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.